Skip to content
Head to head

Ascentage Pharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: AAPG · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

AAPG -63.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
AAPGVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price11.97515.02
Change today-3.78%-1.08%
1-year return-61.7%+22.0%
Market cap$1.12B$130.58B
52-week range11.97 – 33.09412.27 – 568.67
Valuation
P/E (TTM)-5.0733.14
P/E percentile, own 5-yr range98th99th
P/B13.396.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.0015.32
Net profit (TTM)$-186.50M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date--2026-09-29
Revenue growth (YoY)--+11.8%
Gross margin93.9%85.5%
Operating margin-216.7%33.1%
Net margin-228.5%30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date--2026-09-29
Ownership & sentiment
Institutional ownership26.2%96.8%
Insider activity (12mo)6 buy / 0 sell28 buy / 22 sell
Short interest (% of float)0.0%1.9%
Analyst consensus100% buy (7)95% buy / 5% hold (21)
Analyst price target$42 (+251%)$624 (+21%)
StockVane view
StockVane Quant RatingE (3)C (68)
Company
Employees7676,400
Founded20091989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.